

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/623,728
		Filing Date	January 22, 2001
		First Named Inventor	ZAGHOUBANI, Habib
		Art Unit	1644
		Examiner Name	SZPERKA, Michael E.
Sheet 1	of 1	Attorney Docket Number 8114-005-WO-CIP.2-US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MS/		MARKETLETTER, AutoImmune Shares Collapse on Colloral Data in Rheumatoid Arthritis, 13 September 1999, Marketletter Publications, UK.	
/MS/		ANDERTON, S. M., Peptide-Based Immunotherapy of Autoimmunity: A Path of Puzzles, Paradoxes and Possibilities, Immunol, 2001, 104, 367-376.	
/MS/		DONG, V. M., et al. Transplantation Tolerance: The Concept and Its Applicability, Ped. Transplan. 1999, 3, 181-192.	
/MS/		LEGGE, K.L., et al. TCR Agonist and Antagonist Exert In Vivo Cross-Regulation When Presented on Igs, J. Immunol. 1998;161:106-111.	

Examiner Signature	/Michael Szperka/	Date Considered	07/27/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.